"The successful on-time completion of cGMP manufacturing of the RC220 bisantrene formulation was a highlight of the quarter with a Certificate of Analysis (CoA) issued confirming the new formulation meets the specifications required for a human intravenous (IV) drug product."
TICK!!!
Ann: Quarterly Activity Report & Appendix 4C, page-2
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.42 |
Change
0.000(0.00%) |
Mkt cap ! $242.0M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 12405 | $1.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 3055 | 2 |
View Market Depth
| Last trade - 07.00am 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable